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Abstract 
Aminoacyl-tRNA synthetase-interacting multi-functional protein 2 (AIMP2) works as potent 
tumor suppressor, while its splicing variant lacking exon 2 (AIMP2-DX2) competes with AIMP2 for 
binding to target proteins and compromises its anti-tumor activity. Assuming that AIMP2 and its 
variant AIMP2-DX2 could be released out to human sera in pathological condition, we investigated 
the diagnostic and prognostic usefulness of autoantibodies against AIMP2 and AIMP2-DX2 by 
measuring their serum levels in 80 normal and lung cancer samples that were matched in age, 
gender and smoking status. The area under the curve of AIMP2-DX2, AIMP2, and 
AIMP2-DX2/AIMP2 autoantibody ratio was low (0.416, 0.579, and 0.357, respectively), suggesting 
limited diagnostic value. A total of 165 lung cancer patients were classified into low and high 
AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 based on the median expression of each parameter. 
The high AIMP2-DX2 group was older and had larger tumors (>3 cm) than the low AIMP2-DX2 
group. The high AIMP2-DX2/AIMP2 group had higher CYFRA-21 levels and significantly shorter 
overall survival than the low AIMP2-DX2/AIMP2 group (18.6 vs. 48.9 months, P = 0.021, Log Rank 
Test). Taken together, autoantibodies against AIMP2-DX2 and AIMP2 are detectable in the human 
blood and the increased ratio of AIMP2-DX2/AIMP2 is related to poor clinical outcome of lung 
cancer. 
Key words: Aminoacyl t-RNA synthetase (ARS), Aminoacyl t-RNA synthetase-interacting multi-functional 
protein 2 (AIMP2), Aminoacyl t-RNA synthetase-interacting multi-functional protein 2–exon 2 deletion 
(AIMP2-DX2), Autoantibody, Lung cancer. 
Introduction 
Lung cancer is the second most common 
malignancy, accounting for more than one-quarter of 
all cancer deaths in the United States.[1] Despite the 
unremitting efforts toward biomarker discovery and 
the development of targeted therapy and 
immunotherapy, lung cancer is by far the leading 
cause of cancer death with poor prognosis. 
Development of effective tools for early diagnosis and 
new therapeutic strategies based on lung cancer 
biology are urgently needed to improve its clinical 
outcome. 
Aminoacyl-tRNA synthetase-interacting multi- 
functional proteins (AIMPs) are scaffolding proteins 
for the assembly of the macromolecular tRNA 
synthetase complex. Among the 3 types of AIMPs, 








anti-proliferative and cell death-promoting activity 
through multiple pathways such as tumor-derived 
growth factor (TGF)-β, p53, tumor necrosis factor 
(TNF)-α signaling and Wnt signaling.[2-8] Mice 
lacking AIMP2 die neonatally due to respiratory 
failure resulting from uncontrolled proliferation of 
lung epithelial cells. AIMP2 heterozygous mice (with 
reduced expression of AIMP2) show a higher 
susceptibility to tumorigenesis.[5] These findings 
indicate that AIMP2 is a haploinsufficient tumor 
suppressor with a unique working mechanism.[2]  
A variant of AIMP2 in which exon 2 is deleted by 
alternative splicing, AIMP2-DX2, has been detected in 
cancer cell lines and tissues.[9] AIMP2-DX2 competes 
with AIMP2 for the binding to target proteins (namely 
FUSE-binding protein [FBP], TNF receptor-associated 
factor 2 [TRAF2], and p53), consequently inhibiting 
the tumor suppressive activity of AIMP2. Increased 
ratio of AIMP2-DX2 versus AIMP2 showed positive 
correlation to poor clinical outcome of lung cancer, as 
well as chemoresistance of ovarian cancer.[2, 9] The 
synthetic compound, BC-DXI01suppressed the 
AIMP2-DX2 mRNA transcript, leading to the 
inhibition of the AIMP2-DX2 activity and tumor 
suppression.[10] Taken together, these data suggest 
that AIMP2-DX2 is an attractive candidate for cancer 
diagnosis and therapy. 
In this study, AIMP2-DX2 expression was 
examined in lung cancer using Kras and Kras:p53fl/fl 
mouse lung cancer models and human lung cancer 
tissues. Moreover, the presence of autoantibodies 
against AIMP2-DX2 and AIMP2 in the blood was 
investigated by enzyme-linked immunosorbent assay 
(ELISA). We sought to find the diagnostic and 
prognostic usefulness of these autoantibodies in lung 
cancer patients. 
Materials and Methods 
Tissue samples 
Mouse tissues were obtained from wild-type 
C57BL/6, LSL-Kras G12D, and LSL-Kras G12D:p53fl/fl 
mice. For mouse lung cancer tissues, LSL-Kras G12D 
and LSL-Kras G12D:p53fl/fl mice 
(http://mouse.ncifcrf.gov/) inhaled 5 × 107 PFU 
AdCre particles at 8 weeks of age and sacrificed at 8 
and 24 weeks after inhalation, respectively. This 
animal study was approved by our Institutional 
Animal Care and Use Committee (2014-0229-1), 
following the guidelines of the American Association 
for the Assessment and Accreditation of Laboratory 
Animal Care. A total of 275 formalin-fixed, 
paraffin-embedded human lung cancer tissues, and 12 
pairs of lung cancer and adjacent normal-appearing 
lung tissue lysates were obtained from tissue archives 
of affiliated hospitals of Yonsei University College of 
Medicine. The use of clinical samples was approved 
by the Institutional Review Board of the Severance 
Hospital (#4-2013-0556) and Gangnam Severance 
Hospital (#3-2014-0838). 
Serum samples 
The serum samples from lung cancer patients 
and control subjects were obtained from those who 
had presented to Severance Hospital and Gangnam 
Severance Hospital between 2011 September and 2015 
January. Lung cancer cases were confirmed 
pathologically and did not present with any other 
types of cancer. Control cases were 1:1 age-, gender- 
and smoking status-matched and did not present with 
any type of cancer. A total of 165 samples from lung 
cancer patients were included. Informed consent was 
obtained from all study subjects, and all protocols 
were approved by the Institutional Review Board of 
the Severance Hospital (#4-2013-0556) and Gangnam 
Severance Hospital (#3-2014-0838). The study was 
carried out in accordance with the Declaration of 
Helsinki and Korean GCP guidelines. 
Immunoblotting 
Tissues were harvested using 2× LSB lysis buffer 
containing protease and phosphatase inhibitors 
(GenDepo, Korea) on ice. After homogenization and 
sonication, 30–50 mg of lysates was separated by gel 
electrophoresis on 7.5–12% polyacrylamide gels and 
transferred onto nitrocellulose membranes (Bio-Rad 
Laboratories, Inc., Richmond, CA, USA). The 
expression level of each protein was measured using 
Image J (http://rsbweb.nih.gov/ij/) and quantified 
relative to that of β-actin. 
Immunohistochemistry (IHC) 
Expression of AIMP2-DX2 in mouse lung tissue 
and human lung cancer tissue was analyzed by IHC 
using the LABS®2 System (Dako, Carpinteria, CA, 
USA) according to the manufacturer’s instructions. 
Briefly, sections were deparaffinized, rehydrated, 
immersed in H2O2 methanol solution, and then 
incubated overnight with primary antibodies against 
AIMP2-DX2 obtained by rabbit immunization at a 
1:2,000 dilution. Sections were incubated for 10 
minutes with biotinylated linker and processed using 
avidin/biotin IHC techniques. 3,3 ′
-Diaminobenzidine (DAB) was used as a chromogen 
in conjunction with the Liquid DAB Substrate kit 
(Novacastra, UK). Expression of AIMP2-DX2 was 
evaluated using a scoring system that takes into 
account the product of staining intensity and 
percentage of positive cells. Staining intensity was 
classified as 0, 1, 2, and 3 and frequency was classified 




as 0 (<10%), 1 (10–50%), 2 (51–80%), and 3 (>80%) (Fig. 
S1). The cases were classified into 2 groups according 
to the AIMP2-DX2 expression in the cytoplasm and 
nucleus. Cases with cytoplasmic AIMP2-DX2 
expression intensity and frequency equal to or greater 
than 4 were defined as having high expression; those 
with 3 or less were defined as having low expression. 
Cases with nuclear AIMP2-DX2 expression equal to or 
greater than 1 were defined as having high 
expression; those with 0 were defined as having low 
expression. 
Measurement of serum autoantibodies against 
AIMP2 and AIMP2-DX2 
The 96-well plates were coated with either 
His-tagged AIMP2-DX2 or His-tagged AIMP2 protein 
(Neomix Inc, Korea) overnight at 4°C, and then 
blocked with 1% bovine serum albumin for 1 hour at 
room temperature. After adding 1:500 diluted serum, 
1:10,000 dilution anti-human immunoglobulin G was 
added and incubated for another 1 hour at room 
temperature. The enzyme activity was visualized by 
adding 3,3′, 5,5′-tetramethylbenzidine substrate 
(TMB; Thermo Fisher Scientific) for 10 minutes and 
the reaction was stopped by 2N H2SO4. The 
absorbance was measured at 450 nm was measured. 
The intra-assay variation of AIMP2-DX2 and AIMP2 
was 8.7% (6.8–11.5%) and 6.3% (1.6–10.4%), 
respectively. The inter-assay (plate-to-plate) variation 
was 15.9% (13.7–17.9%) and 12.2% (8.9–16.1%), 
respectively. Lung cancer patients were classified into 
2 groups, high and low, on the basis of the median 
values of AIMP2-DX2, AIMP2, and 
AIMP2-DX2/AIMP2 ratio. 
Statistical analysis 
Significant differences in clinical characteristics 
according to the expression of AIMP2-DX2 by IHC in 
lung tissues, and AIMP2-DX2, AIMP2, and 
AIMP2-DX2/AIMP2 autoantibody ratio were 
analyzed using the χ2-test, Fisher’s exact test, and 
independent 2-sample t-test. Predictive factors for 
overall survival (OS) and progression/recurrence-free 
survival (PFS) were calculated using the 
Kaplan–Meier method and Cox proportional hazards 
model. All tests of significance were 2-tailed. A 
P-value less than 0.05 was interpreted as statistical 
significance. All analyses were performed using SPSS 
version 20 (SPSS Inc., Chicago, IL, USA). 
Results 
AIMP2-DX2 is overexpressed in lung cancer 
tissue 
To explore AIMP2-DX2 as a biomarker of lung 
cancer, its expression was first evaluated in the 
non-neoplastic lung tissue from 8-week-old wild-type 
C57BL/6 mice using the antibody specific to 
AIMP2-DX2 (Fig. S2A). Cells comprising alveolar 
structure did not express AIMP2-DX2, while 
bronchial epithelial cells showed weak expression. To 
evaluate if AIMP2-DX2 expression is specific to lung 
cancer, its expression was evaluated in lung cancer 
tissues. Lung cancer-specific AIMP2-DX2 
overexpression was observed in Kras-LSL G12D and 
Kras-LSL G12D:p53fl/fl murine lung cancer models 
induced by AdCre inhalation (Fig. S2B). The 
expression of AIMP2-DX2 was also evaluated in 
normal-appearing human tissues adjacent to lung 
cancer tissues (Fig. S2C). AIMP2-DX2 was not 
expressed in type I and type II pneumocytes and was 
weakly expressed in the epithelial cells of the 
bronchioles and bronchi. In human lung cancer 
tissues, AIMP2-DX2 was strongly expressed mainly in 
the cytoplasm of adenocarcinoma, squamous cell 
carcinoma, and small cell lung cancer, and weakly 
expressed in large cell carcinoma (Fig. S2D). Lung 
cancer-specific AIMP2-DX2 overexpression was 
further evaluated by immunoblotting. In mouse lung 
tissue, AIMP2-DX2 expression was stronger in lung 
cancer than in normal lungs (Fig. S2E). Among 12 
pairs of human lung cancer tissue and adjacent 
normal-appearing lung tissue, 7 pairs (58.3%) showed 
stronger overexpression of AIMP2-DX2 in lung cancer 
tissue (Fig. S2F). To further validate its clinical 
implication in lung cancer, its expression was 
assessed in 275 formalin-fixed, paraffin-embedded 
lung cancer tissues. The baseline characteristics of the 
275 patients are shown in Table S1. The distribution of 
cytoplasmic and nuclear AIMP2-DX2 expression by 
IHC is shown in Fig. S2G and S2H. Among the 275 
patients, 270 (98.2%) showed positive cytoplasmic 
AIMP2-DX2 expression while 91 (33.1%) showed 
positive nuclear AIMP2-DX2 expression. The clinical 
and pathological characteristics of patients with high 
and low cytoplasmic/nuclear expression are shown in 
Table S2. High cytoplasmic (39.6% vs. 28.6%, P = 
0.055) and nuclear AIMP2-DX2 expression (42.9% vs. 
30.4%, P = 0.042) was more frequent in advanced 
stages (III–IV) than in earlier stages (I–II). High 
cytoplasmic (58.2% vs. 40.2%, P = 0.003) and nuclear 
AIMP2-DX2 expression (58.4% vs. 45.8%, P = 0.052) 
was more frequent in adenocarcinoma than in 
squamous cell carcinoma. However, the level of 
AIMP2-DX2 expression was not related with clinical 
outcome, with no significant differences in OS and 
PFS (Fig. S3). 
Autoantibodies against AIMP2-DX2 and 
AIMP2 are detectable in the human blood 
The baseline characteristics of age, gender, and 




smoking habits were not different between lung 
cancer (n = 80) and control patients (n = 80) (Table 1). 
Interestingly, autoantibodies against AIMP2-DX2 and 
AIMP2 were detectable in the serum (Fig. 1A). When 
their diagnostic usefulness was evaluated by receiver 
operating characteristic curve analysis, the area under 
the curve of AIMP2-DX2, AIMP2, and 
AIMP2-DX2/AIMP2 autoantibody ratio was 0.416, 
0.579, and 0.357, respectively, suggesting that their 
diagnostic value in lung cancer is limited (Fig. 1B). 
 
Table 1. Baseline characteristics of control and lung cancer 
patientsa 
Baseline characteristics Control (n=80) Lung cancer 
(n=80) 
P-value 
Age 68.2 ± 12.5 68.5 ± 9.3 0.869 
Gender, male 63 (78.8) 61 (76.3) 0.705 
Smoking status, ever-smoker 59 (73.8) 59 (73.8) 1.000 
Pack years (including 
none-smokers) 
32.6 ± 28.8 35.5 ± 30.5 0.549 
a Data are presented as numbers (percentages) unless otherwise indicated. 





Figure 1. Histogram for distribution of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 autoantibody ratio and receiver operating characteristic 
curve analysis of the diagnostic value for lung cancer. (A) Histogram for distribution of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 autoantibody ratio in 
control and lung cancer patients. (B) Receiver operating characteristic curve of AIMP2, AIMP2-DX2, and AIMP2-DX2/AIMP2 ratio for the diagnosis of lung cancer. 
AIMP2: aminoacyl-tRNA synthetase-interacting multi-functional protein 2, AIMP2-DX2: aminoacyl-tRNA synthetase-interacting multi-functional protein 2–exon 2 
deletion 




AIMP2-DX2 autoantibody levels are related 
with tumor size 
AIMP2-DX2 and AIMP2 autoantibody levels 
were measured in 165 lung cancer patients, and the 
AIMP2-DX2/AIMP2 autoantibody ratio was 
calculated. The baseline characteristics of the included 
patients are shown in Table 2. Mean age was 65 years 
and 64.8% of the patients were male. About one-third 
of the patients were never-smokers. According to 
histologic classification, adenocarcinoma was the 
most common type (62.4%), followed by squamous 
cell carcinoma (25.5%). AIMP2-DX2, AIMP2, and 
AIMP2-DX2/AIMP2 autoantibody ratio levels were 
21.6 ± 9.2, 76.7 ± 33.8, and 31.7 ± 13.8 AU, respectively. 
The baseline characteristics of low and high 
AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 ratio 
groups are shown in Table 3. There was no statistical 
difference in gender, smoking, histologic diagnosis, 
and stage between high and low group of 
AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 ratio. 
However, the high AIMP2-DX2 autoantibody group 
was older (66.8 ± 8.4 vs. 63.8 ± 10.1 years, P = 0.040) 
and had larger tumors (>3 cm) (26.9% vs. 12.7%, P = 
0.045) than the low group. Elevated CYFRA-21 levels 
were more frequently observed in the high 
AIMP2-DX2/AIMP2 autoantibody ratio group than 
in the low group (58.8% vs. 41.2%, P = 0.037), but the 
frequency of elevated carcinoembryonic antigen 
(CEA) was similar between the groups. Moreover, the 
mortality rate was higher in the high 
AIMP2-DX2/AIMP2 autoantibody ratio group than 
in the low group (58.5% vs. 42.0%, P = 0.034). 
Table 2. Characteristics of lung cancer patientsa 
Characteristics n=165 
Age, yr 65.3 ± 9.4 
Sex, male 107 (64.8) 
Smoking  
Current 58 (35.2) 
Former 50 (30.3) 
Never 57 (34.5) 
Histology  
Adenocarcinoma 103 (62.4) 
Squamous cell carcinoma 42 (25.5) 
Small cell carcinoma 16 (9.7) 
Large cell carcinoma 4 (2.4) 
Size > 3cmb 23 (18.5) 
Stage (n=149)c  
1 47 (31.5) 
2 8 (5.4) 
3 36 (24.2) 
4 58 (38.9) 
Tumor markers  
Elevated CEAd 74 (49.3) 
Elevated CYFRA 21-1e 68 (47.6) 
Novel markers, AU  
AIMP2-DX2 21.6 ± 9.2 
AIMP2 76.7 ± 33.8 
AIMP2-DX2/AIMP2 31.7 ± 13.8 
Mortality (n=163)f 82 (50.3) 
a Data are presented as numbers (percentages) unless otherwise indicated. 
Plus-minus values are means±standard deviation. 
b n=124 
c Small cell carcinoma was excluded 
d > 5.0 ng/mL, n=150 
e > 3.3 ng/mL, n=143 
f Survival of two patients are unknown 
CEA: carcinoembryonic antigen, AIMP2: aminoacyl-tRNA synthetase interacting 
multi-functional protein 2, AIMP2-DX2: aminoacyl-tRNA synthetase interacting 
multi-functional protein 2–exon 2 deletion (AIMP2-DX2) 
Table 3. Baseline characteristics of low and high AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 autoantibody ratio groupsa 














Age, yr 63.8 ± 10.1 66.8 ± 8.4 0.040  64.1 ± 9.4 66.5 ± 9.3 0.113  64.7 ± 9.5 65.9 ± 9.2 0.443 
Sex, male 52 (63.4) 55 (67.1) 0.623  51 (62.2) 56 (67.5) 0.478  54 (65.9) 53 (63.9) 0.788 
Smoking            
Current 32 (39.0) 26 (31.7) 0.603  27 (32.9) 31 (37.3) 0.484  29 (35.4) 29 (34.9) 0.686 
Former 23 (28.0) 27 (32.9)  23 (28.0) 27 (32.5)  27 (32.9) 23 (27.7) 
Never 27 (32.9) 29 (35.4)  32 (39.0) 25 (30.1)  26 (31.7) 31 (37.3) 
Histology            
Adenocarcinoma 55 (67.1) 48 (57.3) 0.478  53 (64.6) 50 (60.2) 0.216  53 (64.6) 50 (60.2) 0.580 
Squamous cell carcinoma 18 (22.0) 24 (29.2)  16 (19.5) 26 (31.3)  20 (24.4) 22 (26.5) 
Small cell carcinoma 8 (9.7) 8 (9.8)  10 (12.2) 6 (7.2)  7 (8.5) 9 (10.8) 
Large cell carcinoma 1 (1.2) 3 (3.7)  3 (3.7) 1 (1.2)  2 (2.4) 2 (2.4) 
Size > 3cm 9 (12.7) 14 (26.9) 0.045  12 (18.2) 11 (19.0) 0.911  13 (20.0) 10 (16.9) 0.662 
Stage (n=149)            
I-II 34 (41.5) 27 (33.3) 0.284  28 (34.1) 34 (41.5) 0.334  36 (44.4) 45 (55.6) 0.083 
III-IV 48 (58.5) 54 (66.7)  54 (65.9) 48 (58.5)  26 (31.3) 57 (68.7) 
Tumor markers            
Elevated CEAc 42 (56.8) 32 (43.2) 0.119  40 (54.1) 34 (45.9) 0.193  35 (47.3) 39 (52.7) 0.514 
Elevated CYFRA-21d 38 (55.9) 30 (44.1) 0.307  37 (54.4) 31 (45.6) 0.278  28 (41.2) 40 (58.8) 0.037 
Mortality 37 (45.1) 45 (56.3) 0.157  42 (51.9) 40 (48.8) 0.695  34 (42.0) 48 (58.5) 0.034 
a Data are presented as numbers (percentages) unless otherwise indicated. Plus-minus values are means±standard deviation. 
b High and low groups were classified on the basis of median value of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 ratio, respectively  
c > 5.0 ng/mL; n=75 for low group, n=75 for high group 
d > 3.3 ng/mL; n=72 for low group, n=71 for high group 
AIMP2: aminoacyl-tRNA synthetase interacting multi-functional protein 2, AIMP2-DX2: aminoacyl-tRNA synthetase interacting multi-functional protein 2–exon 2 deletion (AIMP2-DX2) 




Elevated AIMP2-DX2/AIMP2 autoantibody 
ratio is related with poor clinical outcome in 
lung cancer 
To evaluate the prognostic value of AIMP2-DX2, 
AIMP2, and AIMP2-DX2/AIMP2 autoantibody ratio 
in lung cancer, OS and PFS were compared using 
Kaplan–Meier estimators (Fig. 2). There were no 
significant differences in PFS and OS between low 
and high AIMP2-DX2 and AIMP2 autoantibody 
groups. However, the patients with high 
AIMP2-DX2/AIMP2 autoantibody ratio showed 
significantly shorter OS (18.4 months [95% confidence 
interval (CI) 15.1–21.7] vs. 48.3 months [95% CI 
14.6–81.9], P = 0.021). To evaluate the hypothesis that 
high AIMP2-DX2/AIMP2 ratio is an independent 
prognostic factor in lung cancer, univariate and 
multivariate analyses were performed using a Cox 
regression hazard model (Table 4). Univariate 
analysis revealed that age, female, ever-smoker, 
advanced stages (III–IV), elevated CEA, elevated 
CYFRA-21, and high AIMP2-DX2/AIMP2 
autoantibody ratio were significant predictors for 
poor OS while adenocarcinoma histology was a 
significant predictor for better OS. Multivariate 
analysis showed that advanced stages (III–IV) (HR = 
6.66, 95% CI 3.20–13.89) and high 
AIMP2-DX2/AIMP2 autoantibody ratio (HR = 1.83, 
95% CI 1.11–3.00) were significant independent 
factors for poor OS while adenocarcinoma histology 
(HR = 0.42, 95% CI 0.23–0.76) was a significant 
predictor for better OS. 
 
 
Figure 2. Impact of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 ratio on overall survival and progression/recurrence-free survival in lung cancer 
patients. (A) AIMP2-DX2, (B) AIMP2, and (C) AIMP2-DX2/AIMP2 ratio. High and low groups were classified on the basis of the median values of AIMP2-DX2, AIMP2, and 
AIMP2-DX2/AIMP2 ratio. P-values were obtained by the log-rank test. AIMP2: aminoacyl-tRNA synthetase-interacting multi-functional protein 2, AIMP2-DX2: aminoacyl-tRNA 
synthetase-interacting multi-functional protein 2–exon 2 deletion, OS: overall survival, PFS: progression/recurrence-free survival 




Table 4. Univariate and multivariate Cox-regression analysis of overall survival 
Characteristics Univariate Analysis  Multivariate Analysis 
HR P-value 95% CI  HR P-value 95% CI 
Age, yr 1.03 0.022 1.00 - 1.06  1.02 0.201 0.99 - 1.05 
Sex, female 0.53 0.011 0.32 - 0.86  0.76 0.655 0.22 - 2.58 
Smoking, ever-smoker 1.71 0.029 1.06 - 2.77  1.12 0.858 0.33 - 3.77 
Histology        
Adenocarcinoma 0.54 0.006 0.35 - 0.84  0.42 0.004 0.23 - 0.76 
Squamous cell carcinoma 1.51 0.084 0.95 - 2.42     
Size > 3cm 0.56 0.180 0.24 - 1.31     
Stage, stage III-IV vs. I-II 6.71 < 0.001 3.45 - 13.05  6.66 < 0.001 3.20 - 13.88 
Tumor markers        
Elevated CEAa 1.92 0.007 1.20 - 3.07  1.44 0.176 0.85 - 2.42 
Elevated CYFRA-21b 2.98 < 0.001 1.82 - 4.86  1.40 0.231 0.81 - 2.41 
Novel markersc        
High group of AIMP2-DX2 1.28 0.263 0.83 - 1.98     
High group of AIMP2 0.88 0.579 0.57 - 1.37     
High group of AIMP2-DX2/AIMP2 1.67 0.023 1.07 - 2.60  1.83 0.018 1.11 - 3.00 
a > 5.0 ng/mL 
b > 3.3 ng/mL 
c High group was classified on the basis of median value of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 ratio, respectively 
AIMP2: aminoacyl-tRNA synthetase interacting multi-functional protein 2, AIMP2-DX2: aminoacyl-tRNA synthetase interacting multi-functional protein 2–exon 2 deletion 
(AIMP2-DX2), HR: hazard ratio, CI: confidence interval 
 
Discussion 
This study investigated the clinical implications 
of AIMP2-DX2 tissue expression and serum 
autoantibodies in lung cancer patients. Although 
AIMP2-DX2 was frequently overexpressed in lung 
cancer tissues, and associated with advanced disease 
stages and adenocarcinoma, diagnostic usefulness of 
AIMP2-DX2 autoantibody was limited. 
Autoantibodies against AIMP2-DX2 and AIMP2 exist 
at detectable level in human blood and increased 
AIMP2-DX2/AIMP2 autoantibody ratio was an 
independent prognostic factor for poor OS in patients 
with lung cancer.  
Although several reports have suggested the 
tumor promoting role of AIMP2-DX2, a potential of 
AIMP2-DX2 as a biomarker for cancer diagnosis, 
treatment, and prognosis prediction is limited.[2-7] In 
this study, we used immunohistological analysis 
using AIMP2-DX2-specific antibody to directly 
monitor AIMP2-DX2 at protein level rather than its 
transcript level and found its frequent increase 
(54.2%) in NSCLC tissues.  
There are pressing needs for the development of 
blood biomarkers because it is convenient and less 
invasive. There are a few biomarkers for the diagnosis 
and prognosis prediction in lung cancer and their 
usefulness is hampered because of low diagnostic and 
prognostic value.[11-13] Although it was unclear 
whether the soluble and secretory form of 
AIMP2-DX2 would exist in the blood, its 
autoantibody was detectable in the blood and showed 
the correlation with serum CYFRA 21-1 (γ = 0.133, P = 
0.056; data not shown), a soluble fragment of 
cytokeratin 19 filaments.[14, 15] 
The clinical implication of AIMP2, AIMP2-DX2 
autoantibody and AIMP2-DX2/AIMP2 autoantibody 
ratio was investigated for the first time in this study 
from lung cancer patients. AIMP2-DX2/AIMP2 
autoantibody ratio was suggested as a potential 
prognostic biomarker in lung cancer patients while 
AIMP2-DX2 autoantibody alone was not. The 
competitive interaction between AIMP2-DX2 and 
AIMP2 for binding to the target proteins could be 
related to the prognostic value of 
AIMP2-DX2/AIMP2 ratio. 
Although this study presented a potential of 
AIMP2-DX2 as a potential biomarker in lung cancer, 
there are a few limitations to be addressed. First, the 
diagnostic and prognostic value of AIMP2-DX2 as 
determined by IHC and autoantibody levels needs to 
be compared in the specimens obtained from the same 
subjects at the same time point. The relationship 
between AIMP2-DX2 in the tissue and in the blood is 
important for further clarifying the role of 
AIMP2-DX2 in cancer formation and progression. 
Second, development of direct measurement of 
AIMP2-DX2 and AIMP2 in the blood would be also 
needed to overcome the limitation of autoantibody 
analysis. Future studies should compare the secretory 
form of AIMP2-DX2/AIMP2 and autoantibodies 
against AIMP2-DX2/AIMP2 as suitable biomarkers in 
lung cancer. In conclusion, autoantibodies against 
AIMP2-DX2 and AIMP2 were detectable in blood. The 
increased ratio of AIMP2-DX2/AIMP2 autoantibodies 
was related to the poor clinical outcome of lung 
cancer patients, suggesting its potential as a 
prognostic marker in lung cancer.  
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AIMP2: aminoacyl t-RNA synthetase-interacting 
multi-functional protein 2; AIMP2-DX2: aminoacyl 
t-RNA synthetase-interacting multi-functional protein 
2–exon 2 deletion; ARS: aminoacyl t-RNA synthetase; 
CEA: carcinoembryonic antigen; CI: confidence 
interval; FBP: FUSE-binding protein; IHC: 
immunohistochemistry; ELISA: enzyme-linked 
immunosorbent assay; OS: overall survival; PFS: 
progression/recurrence-free survival; TGF: 
tumor-derived growth factor; TNF: tumor necrosis 
factor; TRAF2: TNF receptor-associated factor 2. 
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